Epithelium removal not necessary for collagen cross-linking

Article

Corneal collagen cross-linking with riboflavin, without removing the epithelium, is both safe and effective.

Corneal collagen cross-linking with riboflavin, without removing the epithelium, is both safe and effective, according to Roberto Pinelli, ILMO, Brescia, Italy.

Dr Pinelli examined two groups of five keratoconic patients. Group A was treated monocularly without removing the epithelium and Group B was treated after epithelial removal. Custom-made riboflavin eye-drops were applied to the cornea and activated by UV-A.

Dr Pinelli noted no significant differences between the two groups postoperatively. The 30 eyes in Group A, at 18 months follow-up, showed a mean K reduction of 0.83 D, higher K reduction in the 3 mm central zone, a mean uncorrected visual acuity (UCVA) improvement of 1.3 lines, a mean best spectacle corrected visual acuity (BSCVA) and an increase in central pachymetry. Furthermore, keratoconus progression was halted in all eyes.

These results demonstrate that it is not necessary to remove the epithelium in order for riboflavin to effectively penetrate the cornea.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.